Skip to main content

Table 4 Patient details of grade ≥ 2 irAEs and treatment cycles, OR at the time of irAEs onset

From: Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

Case

irAEs

Treatment cycles

OR

Continuity

1

Grade 3 pneumonitis, grade 2 hypothyroidism

14

SD

Discontinue

2

Grade 3 hypophysitis

18

SD

Discontinue

3

Grade 2 pneumonitis

31

PR

Discontinue

4

Grade 2 hypothyroidism

3

SD

Continue

5

Grade 2 rash maculopapular

17

SD

Continue

6

Grade 2 bullous dermatitis

3

PR

Continue

  1. OR objective response, CR complete response, PR partial response, SD stable disease